Drug Trial Radar · NCT06408935
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Actual
Start
Apr 17, 2024
Primary completion
Jun 8, 2027
Study completion Mar 6, 2028
Sponsor
- Lead sponsor
- Janssen-Cilag Ltd.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Conditions
- Crohn's Disease
Interventions
GuselkumabDrug
Guselkumab will be administered IV and SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a Magnetic Resonance Index of Activity (MaRIA) Less Than (<)11 in All Intestinal Segments at Week 48Time frame: At Week 48
Locations
84 sites in 14 countries. Site status is shown where the registry gives one.
Center for Colitis and Crohns Disease University of California
San Francisco, California
The University of Chicago Medical Center (UCMC)
Chicago, Illinois
Washington University School Of Medicine
St Louis, Missouri
Medical University of South Carolina
Charleston, South Carolina
The Queen Elizabeth Hospital
Adelaide, Australia
Concord Repatriation General Hospital
Concord, Australia
Northern Hospital
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Mater Hospital Brisbane
South Brisbane, Australia
AZ Maria Middelares
Ghent, Belgium
CHU de Liege
Liège, Belgium
Vitaz
Sint-Niklaas, Belgium
Cliged
Macaé, Brazil
Instituto Mederi de Pesquisa e Saude
Passo Fundo, Brazil
NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
Porto Alegre, Brazil
INTEGRAL Pesquisa e Ensino
Votuporanga, Brazil
Foothills Hospital
Calgary, Alberta, Canada
Western University & London Health Sciences Centre
London, Ontario, Canada
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, Canada
Nemocnice Ceske Budejovice a s
České Budějovice, Czechia
Hepato-gastroenterologie HK, s.r.o.
Hradec Králové, Czechia
ISCARE a.s.
Prague, Czechia
CHU Amiens Picardie
Amiens, France
CHU de Clermont Ferrand
Clermont-Ferrand, France
CHRU de Lille Hopital Claude Huriez
Lille, France
Aphm - Hopital Nord
Marseille, France
CHU de Nantes hotel Dieu
Nantes, France
APHP - Hopital Bichat - Claude Bernard
Paris, France
Klinikum Augsburg
Augsburg, Germany
Charite Universitaetsmedizin Berlin
Berlin, Germany
Praxis Fur Gastroenteroligie
Berlin, Germany
Medizinisches Versorgungszentrum (MVZ) Dachau
Dachau, Germany
Universitatsklinikum Frankfurt/ Medizinische Klinik 1
Frankfurt, Germany
Universitatsmedizin Gottingen
Göttingen, Germany
Studiengesellschaft Mitteldeutschland GmbH
Halle, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitatsklinikum Schleswig Holstein
Kiel, Germany
Staedtisches Klinikum Lueneburg
Lüneburg, Germany
MVZ Portal 10
Münster, Germany
Siloah St Trudpert Klinikum
Pforzheim, Germany
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.